{"id":768680,"date":"2023-07-10T16:12:12","date_gmt":"2023-07-10T20:12:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/"},"modified":"2023-07-10T16:12:12","modified_gmt":"2023-07-10T20:12:12","slug":"inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/","title":{"rendered":"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology"},"content":{"rendered":"
\n

\n
\n Neutralizing soluble TNF with XPro\u2122 promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses<\/i>
\n <\/b>\n <\/p>\n

\n Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) — \u00a0<\/strong>
\n
\n INmune Bio, Inc.<\/strong>
\n \u00a0<\/u>
\n <\/a>(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announces\u00a0important findings from data presented at The 16th<\/sup> European Meeting on Glial Cells in Health and Disease.\u00a0 The conference\u00a0runs July 8-12 in Berlin, Germany. <\/p>\n

Myelin is a specialized lipid produced by oligodendrocytes that forms the myelin sheath of axons. \u00a0Axons are the projections that allow neurons to communicate with each other and with other tissues such as muscle, skin, retina, nose and the ear for sight, smell and hearing respectively.\u00a0 An intact and healthy myelin sheath is necessary for axons to work properly.\u00a0 Any damage to the myelin sheath compromises axon function preventing nerve cells from communicating and can result in nerve cell death.\u00a0 Although the pathology of demyelination is easy to see, the biology of demyelination and remyelination is poorly understood. \u00a0Drug therapy to prevent demyelination are available, but there are no therapies that promote remyelination.\u00a0 Therapies that promote remyelination will be needed to effectively treat many neurodegenerative diseases.<\/p>\n

\u201cDemyelination is an important part of the pathology of many neurodegenerative diseases including multiple sclerosis (MS) and Alzheimer\u2019s disease (AD).\u00a0 In the past, microglia cells were thought to drive demyelination,\u201d said Prof. Lesley Probert Ph.D. from the Hellenic Pasteur Institute in Athens, Greece. \u00a0\u201cThis work\u00a0shows that astrocytes, the most abundant cell in the brain after neurons, like microglia, are intimately involved in driving the neuroinflammation component in demyelinating diseases, and that blocking soluble TNF with XPro\u2122 promotes remyelination.\u201d\u00a0 Prof. Probert\u2019s team has previously shown that XPro\u2122 promotes remyelination in the cuprizone model \u2013 a standard model for studying myelin biology in the brain.\u00a0 Work continues to determine how XPro\u2122 affects microglia and astrocyte responses to promote disease resolution and repair.\u00a0 The data presented today demonstrate new findings.\u00a0 First, astrocytes are rapidly activated in response to demyelination.\u00a0Second, preventing soluble TNF and TNFR1 function in mice using microglia- or astrocyte-specific TNFR1 knockout mice mirrors the effects of\u00a0XPro\u2122 in increasing beneficial glial responses that results in better remyelination. The third surprise is that traditional biomarkers of astroglial and microglial activation, GFAP and Iba1 respectively, are increased in these myelin-promoting glial cells.<\/p>\n

“Until recently, the of role in demyelination and remyelination has been poorly understood. This work shows that microglia and astroglia must express biomarkers of activation to promote remyelination,\u201d said Dr. CJ Barnum VP of CNS Drug Development at INmune Bio.\u00a0 “This finding is contrary to current dogma that suggests decreased glial activation is required to promote remyelination. This finding supports our belief that immunosuppressive therapies that turn off the glial cells will not help repair and regeneration of the brain in neurologic diseases.”\u00a0 These data will be expanded in a detailed publication in the future.<\/p>\n

\n List of Presentations:<\/b>\n <\/p>\n

\n Distinct astrocyte activation profiles associated with demyelination in the cuprizone model of multiple sclerosis.<\/b>\n <\/p>\n

\n Therapeutic modulation of solTNF-TNFR1 signaling selectively in microglia promotes remyelination in the cortical grey matter.<\/b>\n <\/p>\n

\n About INmune Bio, Inc.<\/b>\n <\/p>\n

\n
\n
\n INmune<\/u>
\n <\/b>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>
\n
\n
\n Bio,<\/u>
\n <\/b>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>
\n
\n
\n Inc<\/u>
\n <\/b>
\n <\/a>. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trials to determine if it can treat cancer (INB03\u2122), early Alzheimer\u2019s disease, and treatment resistant depression (XPro\u2122). The Natural Killer Cell Priming Platform includes INKmune\u2122 aimed at priming the patient\u2019s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio\u2019s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit\u00a0www.inmunebio.com<\/u><\/b><\/a>.<\/p>\n

\n Forward Looking Statements<\/b>\n <\/p>\n

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.\u00a0 Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03\u2122, XPro1595\u2122, and INKmune\u2122 are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.<\/p>\n

\n INmune Bio Contact:<\/strong>\n <\/p>\n

David Moss, CFO
(858) 964-3720
info@inmunenbio.com<\/u><\/a><\/p>\n

\n Investor Contact:<\/strong>
\n
\n
\n <\/b>Jason Nelson
Core IR
(516) 842-9614 x-823<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Neutralizing soluble TNF with XPro\u2122 promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) — \u00a0 INmune Bio, Inc. \u00a0 (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announces\u00a0important findings from data presented at The 16th European Meeting on Glial Cells in Health and Disease.\u00a0 The conference\u00a0runs July 8-12 in Berlin, Germany. Myelin is a specialized lipid produced by oligodendrocytes that forms the myelin sheath of axons. \u00a0Axons are the projections that allow neurons to communicate with each other and with other tissues such as muscle, skin, retina, nose and the ear for sight, smell … <\/p>\n

Continue reading “INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768680","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nINmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Neutralizing soluble TNF with XPro\u2122 promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) — \u00a0 INmune Bio, Inc. \u00a0 (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announces\u00a0important findings from data presented at The 16th European Meeting on Glial Cells in Health and Disease.\u00a0 The conference\u00a0runs July 8-12 in Berlin, Germany. Myelin is a specialized lipid produced by oligodendrocytes that forms the myelin sheath of axons. \u00a0Axons are the projections that allow neurons to communicate with each other and with other tissues such as muscle, skin, retina, nose and the ear for sight, smell … Continue reading "INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T20:12:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology\",\"datePublished\":\"2023-07-10T20:12:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/\"},\"wordCount\":1054,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/\",\"name\":\"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==\",\"datePublished\":\"2023-07-10T20:12:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/","og_locale":"en_US","og_type":"article","og_title":"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology - Market Newsdesk","og_description":"Neutralizing soluble TNF with XPro\u2122 promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) — \u00a0 INmune Bio, Inc. \u00a0 (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announces\u00a0important findings from data presented at The 16th European Meeting on Glial Cells in Health and Disease.\u00a0 The conference\u00a0runs July 8-12 in Berlin, Germany. Myelin is a specialized lipid produced by oligodendrocytes that forms the myelin sheath of axons. \u00a0Axons are the projections that allow neurons to communicate with each other and with other tissues such as muscle, skin, retina, nose and the ear for sight, smell … Continue reading \"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-10T20:12:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology","datePublished":"2023-07-10T20:12:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/"},"wordCount":1054,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/","name":"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==","datePublished":"2023-07-10T20:12:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTgzMiM1Njg1MDQzIzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-health-and-disease-shows-that-xpro-promotes-remyelination-by-affecting-astroglial-and-microglial-biolog\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro\u2122 Promotes Remyelination by Affecting Astroglial and Microglial Biology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768680"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768680\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}